Prolactin – a marker of the activity of connective tissue systemic disease?

Česká verzia

Authors: Ž. Macejová ¹; D. Trejbal ²; M. Oetterová ¹; I. Lazúrová ¹
Authors place of work: I. Interná klinika Lekárskej fakulty UPJŠ a FN L. Pasteura Košice, Slovenská republika, prednostka prof. MUDr. Ivica Lazúrová, CSc. ¹; IV. interná klinika Lekárskej fakulty UPJŠ a FN L. Pasteura Košice, Slovenská republika, prednosta prof. MUDr. Ivan Tkáč, CSc. ²
Published in the journal: Vnitř Lék 2008; 54(11): 1039-1044
Category: Original Contributions

Summary

The ethiopathogenesis of auto-immune diseases has not yet been fully explored. Auto-immune diseases develop in individuals with a genetic pre-disposition. Among the endogenous factors, also sexual hormones play a role, especially prolactin. The objective of the study was to use basal exam and TRH test to determine stimulated prolactin values in patients with a systemic connective tissue disease: systemic lupus erythematosus (SLE), systemic sclerosis, Sjögren’s syndrome, dermatomyositis.

Patient group and methods:
The authors examined 43 patients with systemic connective tissue diseases: 20 patients with SLE, 7 patients with Sjögren’s syndrome, 7 patients with systemic sclerosis and 9 patients with dermatomyositis. The mean age of the patients was 39.87 years. The control group consisted of 30 volunteers with a mean age of 35.17 years.

Outcome:
Prolactin level in the patients with systemic connective tissue diseases was 14.629 ng/ml, which is more than in the control group. A statistically significant increase in prolactin level was recorded 20 minutes after i.v. stimulation as compared with the control group (30.982 ng/ml). This statistically significant difference was still present 60 minutes after the TRH administration, with 16.43 ng/ml in the control group, and 36.890 ng/ml in the systemic connective tissue disorder patient group. The differences between prolactin levels for the different systemic connective tissue diseases were not statistically significant. A positive correlation in the patient group was found between the stimulated prolactin values and the FW value. On the whole, however, there was no clear correlation found between laboratory activity and prolactin levels.

Conclusion:
The authors found out that post-stimulation prolactin levels were statistically significantly higher in patients with systemic connective tissue disease as compared with the control group. Correlation analyses did not show a clear link between inflammatory activity and prolactin levels, and therefore the authors assume that medium increased values of prolactin are rather a risk factor for the disease than an inflammation marker in patients with a systemic connective tissue disease.

Key words:
prolactin – systemic connective tissue disease – disease activity

Zdroje

1. Blanco-Favela F, Alvarez G Q, Miranda AL. Association between prolactin and disease activity in systematic lupus erythematosus. Influence of statistical power. J Rheumatol 1999; 26: 55–59.

2. Buskila D, Berezin M, Gur Het al. Autoantibody profile in the sera of women with hyperprolactinemia. J Autoimmun 1995; 8: 415–524.

3. Cebecauer L, Kozáková D, Bošák V. Autoimunita a autoprotilátky pri systémových reumatických chorobách: In: Rovenský J et al. Reumatológia v teórii a praxi IV. Martin: Osveta 1996, 36–58.

4. El-Graft A, Salah S, Shaarawy M et al. Prolactin hormone in juvenile systemic lupus erythematosus: A possible relationship to disease activity and CNS manifestations. J Rheumatol 1996; 23: 374– 377.

5. Dostál C, Moszkorová L, Musilová L et al. Serum prolactin stress values in patients with systemic lupus erythematosus. Ann Rheum Dis 2003; 62: 487–488.

6. Dostál C, Marek J. Prolaktin – významný činiteľ vzťahu medzi neuroendokrinným a imunitným systémom človeka – editorial. Vnitř Lék 2005; 51: 1228–1231.

7. Jara LJ, Silviera LH, Cuellar MI et al. Hyperprolactinaemia in Reiter’s syndrome. J Rheumatol 1994; 21: 1292–1297.

8. Jimena P, Aguirre MA, Lopez-Corbelo A et al. Prolactin levels in patients with systemic lupus erythematosus: a case controlled study. Lupus 1998; 7: 383–386.

9. Jorgensen C, Bressot N, Bolognac C et al. Dysregulation of the hypothalamo-pituitary axis in the rheumatoid arthritis. J Rheumatol 1995; 22: 1829–1833.

10. Jorgensen C, Mazaid H, Bologna C et al. Kinetics of prolactin release in a rheumatoid arthritis. Clin Exp Rheumatol 1995; 13: 705–709.

11. Kawai T, Katoh K, Tani K. Hyperprolactinemia preceding development of autoimmune disease. J Rheumatol 1996; 23: 1483–1484.

12. Macejová Ž, Nagyová I, Trejbal D et al. Vzťah medzi hodnotami prolaktínu a mierou funkčnej neschopnosti hodnotenej dotazníkom HAQ u pacientov sreumatoidnou artritídou. Vnitř Lék 2005; 51: 1260–1265.

13. McMuray RW, Allen SH, Pepmeuller PH et al. Elevated serum prolactin levels in children with juvenile rheumatoid arthritis and antinuclear antibodies seropositivity. J Rheumatol 1995; 22: 1577–1580.

14. Neidhard M. Elevated serum prolactin or elevated prolactin/cortisol ratio are associated with autoimmune processes in systemic lupus erythematosus and other connective tissue diseases. J Rheumatol 1996; 23: 478–481.

15. Neidhart M. Prolactin in autoimmune disease. Proc Soc exp Biol Med 1998; 217: 408–419.

16. Rezaieyazdi Z, Hesamifard A. Correlation between serum prolactin levels and lupus activity. Rheumatol Int 2006; 26: 1036–1039.

17. Rovenský J, Dostál C, Lukáč J et al. Systémový lupus erythematosus. In: Ďuriš I et al. Princípy internej medicíny. Bratislava: Slovak Academic Press 2001, 1425–1434.

18. Rovenský J, Blažíková S, Rauová L et al. The hypothalamic-pituitary response in SLE. Regulation of prolactin, growth hormone and cortisol release. Lupus 1998; 7: 409–413.

19. Rovenský J, Bakošová J, Koska J et al. Somatotropic, lactotropic and adrenocortical responses to insulin‑induced hypoglycemia in patients with rheumatoid arthritis. Ann NY Acad Sci 2002; 966: 263–270.

20. Rovenský J, Bakošová J, Payer J et al. Increased demand for steroid therapy in hyperprolactinemic patients with rheumatoid arthritis. Int J Tissue React 2001; 23: 145–149.

21. Szilasiová J, Klímová E. Susac Syndrome: Retinocochleocerebral Vasculopathy. Croatian Medical Journal 2004; 45: 228–343.

22. Vera-Lastra O, Jara LJ, Medina G et al. Functional hyperprolactinemia and hypophyseal microadenoma in systemic sclerosis. J Rheumatol 2006; 33: 1108–1112.